Get the Stockscreener App
2.75
1.48%
0.04
After Hours:
2.65
-0.10
-3.64%
Sunshine Biopharma Inc stock is traded at $2.75, with a volume of 70,180.
It is up +1.48% in the last 24 hours and up +7.42% over the past month.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. The company is conducting a proprietary drug development program which is comprised of (i) K1.1 mRNA targeted for liver cancer, (ii) SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections, and (iii) Adva-27a for pancreatic cancer. The company has two reportable segments: Prescription Generic Pharmaceuticals ("Generic Pharmaceuticals") and Nonprescription Over-The-Counter Products ("OTC Products"). The company generates the majority of its revenue from the Generic Pharmaceuticals segment.
See More
Previous Close:
$2.71
Open:
$2.7
24h Volume:
70,180
Relative Volume:
0.10
Market Cap:
$5.50M
Revenue:
$32.96M
Net Income/Loss:
$-4.23M
P/E Ratio:
-1.6369
EPS:
-1.68
Net Cash Flow:
$-14.00M
1W Performance:
-17.66%
1M Performance:
+7.42%
6M Performance:
-65.00%
1Y Performance:
-99.43%
1-Day Range:
$2.62
$2.758
1-Week Range:
$2.62
$3.44
52-Week Range:
$2.1056
$608.00
Sunshine Biopharma Inc Stock (SBFM) Company Profile
Name
Sunshine Biopharma Inc
Sector
Phone
954-515-0810
Address
333 LAS OLAS WAY, FORT LAUDERDALE
Compare SBFM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SBFM
Sunshine Biopharma Inc
|
2.75 | 5.50M | 32.96M | -4.23M | -14.00M | -155.33 |
|
ZTS
Zoetis Inc
|
178.18 | 80.13B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.76 | 44.29B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.42 | 42.66B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.50 | 18.78B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.63 | 15.03B | 15.05B | -883.30M | 1.89B | -0.74 |
Sunshine Biopharma Inc Stock (SBFM) Latest News
Sunshine Biopharma Inc. Elects New Directors and Ratifies Appointment of Independent Registered Public Accounting Firm - Defense World
Sunshine Biopharma re-elects board, ratifies CPA firm By Investing.com - Investing.com Nigeria
Sunshine Biopharma re-elects board, ratifies CPA firm - Investing.com India
Sunshine Biopharma’s PLpro inhibitor shows activity in SARS-CoV-2 - BioWorld Online
Sunshine Biopharma's Novel COVID-19 Oral Treatment Shows Breakthrough Antiviral Activity in Preclinical Study - StockTitan
Sunshine Biopharma (NASDAQ:SBFM) Stock Quotes, Forecast and News Summary - Benzinga
Sunshine Biopharma Launches a New Generic Prescription Drug - AccessWire
Sunshine Biopharma Launches Generic Allergy Drug in $1.3B Global Bilastine Market - StockTitan
Mouse model studies provide proof of concept for Sunshine Biopharma’s K1.1 mRNA product for HCC - BioWorld Online
Sunshine Biopharma Announces Breakthrough Research Results on the Company’s K1.1 mRNA Product as a Novel Therapeutic Agent for Human Hepatocellular Carcinoma - AccessWire
Sunshine Biopharma's K1.1 mRNA Shows Breakthrough Results in Liver Cancer Treatment - StockTitan
SBFM (Sunshine Biopharma) Cash From Discontinued Investing Activities : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
SBFM (Sunshine Biopharma) Operating Income : $-4.91 Mil (TTM As of Sep. 2024) - GuruFocus.com
SBFM (Sunshine Biopharma) Change In Working Capital : $-7.80 Mil (TTM As of Sep. 2024) - GuruFocus.com
SBFM (Sunshine Biopharma) Debt-to-Equity : 0.02 (As of Sep. 2024) - GuruFocus.com
Alkermes (ALKS) Stock Surges Over 5% Amid Strong Financial Perfo - GuruFocus.com
Stock market today: SKK Holdings Limited +81.83%, Palladyne AI Corp. +50.51% among top gainers in early trading - Business Upturn
Sunshine Biopharma launches generic prescription drug - TipRanks
Sunshine Biopharma launches generic liver drug in Canada - Investing.com
Sunshine Biopharma Launches New Generic Drug in $933M Growing Market | SBFM Stock News - StockTitan
Sunshine Biopharma stock hits 52-week low at $2.3 amid sharp decline - Investing.com Canada
Canopy Growth (CGC) Stock Dives Amid Financial Struggles and Ind - GuruFocus.com
CRON Experiences Significant Stock Dip Amid Market Volatility - GuruFocus.com
Sunshine Biopharma Inc. Warrant (SBFMW) Quarterly 10-Q Report - Quartz
Sunshine Biopharma Reports 2024 Third Quarter Results: Year-To-Date Revenues Up 54% - AccessWire
SBFM (Sunshine Biopharma) Shares Outstanding (EOP) : 1.17 Mil (As of Jun. 2024) - GuruFocus.com
Canopy Growth Corporation (CGC) Stock Declines Amid Financial Re - GuruFocus.com
Bloomin’ Brands (NASDAQ:BLMN) Rating Increased to Hold at StockNews.com - Defense World
StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX) - Defense World
First Citizens Bancshares (OTC:FIZN) Stock Price Down 4.3% – Should You Sell? - Defense World
DBV Technologies (NASDAQ:DBVT) Research Coverage Started at StockNews.com - Defense World
JATT Acquisition (NYSE:JATT) Trading Down 2.7% – Should You Sell? - Defense World
Sunshine Biopharma Strengthens Leadership with New Executive Agreements - TipRanks
Elanco Animal Health (ELAN) Stock Drops 5% Amidst Industry Decli - GuruFocus.com
Sunshine Biopharma, Inc. (NASDAQ:SBFM) Short Interest Up 66.8% in September - MarketBeat
Sunshine Biopharma meets Nasdaq compliance requirements By Investing.com - Investing.com Nigeria
Sunshine Biopharma announces Nora Pharma launch of two new generic drugs - TipRanks
Sunshine Biopharma expands generic drug portfolio - Investing.com
Sunshine Biopharma’s Nora Pharma launches two generic prescription drugs - TipRanks
Sunshine Biopharma Launches Two New Generic Prescription Drugs - AccessWire
A new trading data show Sunshine Biopharma Inc (SBFM) is showing positive returns. - SETE News
Sunshine Biopharma Inc (SBFM) Stock: Navigating a Year of Volatility - The InvestChronicle
How is SBFM’s stock performing after recent trades? - US Post News
Sunshine Biopharma meets Nasdaq compliance requirements - Investing.com
Sunshine Biopharma announces publication of coronavirus research results - TipRanks
Sunshine Biopharma reports potential SARS-CoV-2 treatment By Investing.com - Investing.com Canada
Sunshine Biopharma reports potential SARS-CoV-2 treatment - Investing.com
Sunshine Biopharma Announces Publication of Significant Coronavirus Research Results in the Journal of Medicinal Chemistry - Lelezard
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth - GlobeNewswire
Is Sunshine Biopharma, Inc. (SBFM) The Best Rated Penny Stock To Buy According to Analysts? - MSN
10 Best Rated Penny Stocks To Buy According to Analysts - Insider Monkey
Sunshine Biopharma Inc Stock (SBFM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
0.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):